LYMPHIR Launch Gains Traction: 78% Jump in Ordering Institutions
CTOR sits 29% above its 52-week low of $0.491.
Summary
Citius Oncology's LYMPHIR is showing real commercial momentum. New institutional accounts ordering the drug jumped 78% quarter-over-quarter, with total vial orders up 31%. The therapy is now in 42 institutions, and near-universal payer coverage removes a major access hurdle. This follows the June Phase 1 data presentation showing a 24% overall response rate for the LYMPHIR-pembrolizumab combo. With an expanded sales team now targeting over 250 priority centers and a goal of 100 formulary wins by year-end, the launch trajectory is accelerating. The initial CTCL market exceeds $400 million, and these early metrics suggest LYMPHIR is capturing share quickly.
At the time of this announcement, CTOR was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.4M. The 52-week trading range was $0.49 to $2.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.